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Abstract
Background
Statins are the most common and effective drug used to treat hyperlipidemia. Based on animal studies
showing potential teratogenic effects at high doses, statins are contraindicated in pregnancy due to concern
that they would disrupt cholesterol biosynthesis for the fetus. This review evaluates the current evidence of
harm caused by statins when taken within the first trimester of pregnancy.
Methods
An exhaustive literature search was conducted in June 2015 using MEDLINE-Ovid, CINAHL, Evidence-
Based Medicine Reviews Multifile, and Web of Sciences databases. Keywords searched included statin,
pregnancy, and congenital malformation. The search was further narrowed down to include only English-
language articles and human studies published within the last ten years. Articles within a ten-year period that
evaluated the possible congenital malformations of statin drugs in first trimester women were included. The
Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group
Guidelines was used to evaluate the quality of the remaining eligible articles.
Results Three articles met the inclusion criteria for this systematic review. One retrospective study looked at
886 996 completed pregnancies, 1152 of which took a statin during their first trimester, and found no
significant teratogenic effects from first trimester statin therapy. The second retrospective cohort study with
288 pregnant women found no significant teratogenic effects from first trimester statin therapy. The
prospective observational study included 498 women found no significant teratogenic effects from first
trimester statin therapy. All studies were rated as having low quality of evidence based on GRADE guidelines.
Conclusion
Statins may not be as harmful during pregnancy as the FDA’s class X designation advises, but there is not
enough statistical strength to change the current recommendation of the discontinuation of statins during
pregnancy. Additional research to evaluate the long-term effects of in utero exposure to statins is needed.
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Abstract 
Background 
Statins are the most common and effective drug used to treat hyperlipidemia. Based on 
animal studies showing potential teratogenic effects at high doses, statins are 
contraindicated in pregnancy due to concern that they would disrupt cholesterol 
biosynthesis for the fetus. This review evaluates the current evidence of harm caused by 
statins when taken within the first trimester of pregnancy. 
 
Methods 
An exhaustive literature search was conducted in June 2015 using MEDLINE-Ovid, 
CINAHL, Evidence-Based Medicine Reviews Multifile, and Web of Sciences databases. 
Keywords searched included statin, pregnancy, and congenital malformation. The search 
was further narrowed down to include only English-language articles and human studies 
published within the last ten years. Articles within a ten-year period that evaluated the 
possible congenital malformations of statin drugs in first trimester women were included. 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
Working Group Guidelines was used to evaluate the quality of the remaining eligible 
articles. 
 
Results 
Three articles met the inclusion criteria for this systematic review. One retrospective 
study looked at 886 996 completed pregnancies, 1152 of which took a statin during their 
first trimester, and found no significant teratogenic effects from first trimester statin 
therapy. The second retrospective cohort study with 288 pregnant women found no 
significant teratogenic effects from first trimester statin therapy. The prospective 
observational study included 498 women found no significant teratogenic effects from 
first trimester statin therapy. All studies were rated as having low quality of evidence 
based on GRADE guidelines. 
 
Conclusion 
Statins may not be as harmful during pregnancy as the FDA’s class X designation 
advises, but there is not enough statistical strength to change the current recommendation 
of the discontinuation of statins during pregnancy. Additional research to evaluate the 
long-term effects of in utero exposure to statins is needed.  
 
Keywords 
Statin, pregnancy, congenital malformation 
 
 
 
 
 
 
 
 4 
Acknowledgements 
To Sylvia He, my fiancée, thank you for deciding to move up here to be with me and 
support me both emotionally and financially. You make me happier than I have ever 
been. I love you and I could have never done this without you. 
 
To my parents: I would have never known what a physician assistant was without the two 
of you. You guys gave me the both the idea and the push to become something great. 
Your confidence in me never once wavered. Thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Table of Contents 
Risk of Congenital Malformations With Statin Therapy During the First Trimester of 
Pregnancy .................................................................................................................................................... 1 
Biography .................................................................................................................................................... 2 
Abstract ........................................................................................................................................................ 3 
Acknowledgements .................................................................................................................................. 4 
List of Tables ............................................................................................................................................. 6 
List of Abbreviations ............................................................................................................................... 6 
Risk of Congenital Malformations With Statin Therapy During the First Trimester of 
Pregnancy .................................................................................................................................................... 7 
BACKGROUND ...................................................................................................................................... 7 
METHODS ................................................................................................................................................. 8 
RESULTS ................................................................................................................................................... 9 
DISCUSSION ......................................................................................................................................... 13 
CONCLUSION ...................................................................................................................................... 17 
REFERENCES ....................................................................................................................................... 18 
Table I. Characteristics of Reviewed Studies ................................................................................ 21 
Table II. Summary of Findings .......................................................................................................... 21 
FIGURE I ................................................................................................................................................. 22 
 
 
 
 
 
 
 6 
List of Tables 
Table I: Characteristics of Reviewed Studies 
Table II: Summary of Finding 
 
 
List of Abbreviations 
DMII……………………………………………………………..Diabetes Mellitus Type 2 
FDA………………………………………………………….Federal Drug Administration 
GRADE……….Grading of Recommendations Assessment, Development and Evaluation 
HMG CoA………………………………………….Hydroxymethylglutaryl Coenzyme A 
ICD………………………………………………...International Classification of Disease 
RAMQ………………………………………….Régie de l’Assurance Maladie du Québec 
TIS………………………………………………………...Teratology Information Service 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
Risk of Congenital Malformations With Statin Therapy During the First Trimester 
of Pregnancy 
BACKGROUND 
Hydroxymethyl glutaryl coenzyme A (HMG CoA) reductase inhibitors, also 
known as statins, are the most common drugs to treat hyperlipidemia. Because its 
mechanism of action is primarily to inhibit cholesterol biosynthesis, statins have always 
been contraindicated in pregnancy due to how crucial cholesterol becomes in fetal 
development.1-3 All case reports of statin-exposed pregnancies have been associated with 
lipophilic statins (eg, lovastatin, simvastatin, atorvastatin, and cerivastatin), particularly 
lovastatin,4 which tend to cross the placenta more readily than hydrophilic statins (eg, 
pravastatin, rosuvastatin, and fluvastatin).5 The theory is the high affinity for lipid 
environments will cause these particular statins to cross into extrahepatic tissues, 
including the embryo during pregnancy, thereby disrupting cholesterol biosynthesis.1 A 
study in 2005 with no control group based on spontaneous reporting to the United States 
Food and Drug Administration described 22 incidences of major birth (mostly 
neuromuscular deformities) defects after first-trimester lipophilic statin exposure.6 The 
authors hypothesized that lipophilic statins having higher incidences of teratogenicity is 
due to their role in the dysregulation of the cholesterol synthesis with the Sonic-
Hedgehog gene expression. Hedgehog is a name given to a family of morphogens that 
require the covalent bonding of cholesterol for their functioning. The Hedgehog pathway, 
particularly the Sonic-Hedgehog signaling molecule, is thought to have a critical role in 
the development of the central nervous system, face, skeleton, musculature, and 
viscera.7,8 Other studies however continue to find no evidence of increased risk for fetal 
defects as well as any detectable pattern of birth defects among live births (n = 64).6, 9-12 
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 Obesity rates continue to rise in all age groups. Cardiovascular risk factors, such 
as hyperlipidemia, diabetes, and hypertension have followed suit,13 increasing the amount 
of younger individuals to be started on a statin.14 Half of pregnancies in the United States 
are unintended15,16 and advanced maternal age continues to increase,17 leading to a larger 
overlap between pregnancy and statin therapy, which means a higher rate of accidental 
exposure to statins during pregnancy. A preclinical study18 suggests statins may be able 
to help prevent preeclampsia, a complication that can potentially lead to premature 
delivery of the fetus. With more women on statins becoming inadvertently pregnant and 
indications of statins possibly preventing preeclampsia, there is a need to explore the 
risks and benefits statins have in pregnancy. 
METHODS 
An exhaustive literature search was conducted in June 2015 using MEDLINE-
Ovid, CINAHL, Evidence-Based Medicine Reviews Multifile, and Web of Sciences 
databases. Keywords searched included statins, pregnancy, and congenital malformation. 
The search was further narrowed down to include only English-language articles and 
human studies published within the last ten years. Articles within a ten-year period that 
evaluated the possible congenital malformations of statin drugs in first trimester women 
were included. Meta-analyses, systematic review and case study articles were excluded. 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
Working Group Guidelines was used to evaluate the quality of the remaining eligible 
articles.19 
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RESULTS 
Preliminary results generated 31 articles. Three articles were selected after further 
screening of abstracts and titles to meet inclusion criteria. Retrospective cohort 
studies10,20 were used in two of the articles each using a large database to find women in 
their first trimester that had been exposed to statins. The third study21 was a prospective 
study of women who contacted, or whose physician contacted one of any of the 11 
Teratology Information Services to seek advice about statin exposure in the first trimester 
of pregnancy. See Table I. 
Bateman et al 
This observational retrospective cohort study20 evaluated the risks of major 
congenital malformations as well as specific organ malformations in infants of mothers 
exposed to statins within the first trimester of pregnancy. Cohorts were constructed by 
drawing from Medicaid Analytic eXtract, a database that contains information on 
Medicaid beneficiaries, from 2000-2007. The primary outcome measured congenital 
malformations in the infant. Congenital malformations were defined as central nervous 
system malformations; organ specific malformations; eye, ear, neck, and face, 
malformations; cardiac malformations; respiratory malformations; cleft palate or lip 
malformations; genitourinary malformations; musculoskeletal malformations; or other 
malformations. A congenital malformation was used if there was one identified with 
ICD-9 diagnostic codes on two or more separate days within the first three months of life. 
Covariates such as maternal demographics (eg, age at delivery, race/ethnicity, geographic 
region, year of delivery), obstetric characteristics (ie, multiparity and multiple gestations), 
chronic comorbid medical conditions (defined as diabetes mellitus II, dyslipidemia, pre-
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existing hypertension, chronic renal disease, obesity, alcohol use, tobacco use, or illicit 
drug use) were accounted for. A list of other prescription drugs were examined and those 
taking drugs known to cause teratogenesis were excluded. The primary cohort began with     
886 996 pregnancies, then narrowed down to 1152 women who filled at least two statin 
prescriptions during their first trimester. There were 73 of the 1152 (6.34%) that had 
congenital malformations, compared to the control group having 31 416 of 885 844 
(3.55%). Adjusting for pre-existing diabetes, the relative risk dropped from 1.79 (1.43 to 
2.23) to 1.34 (1.07 to 1.68). Further adjustment for all potential confounders decreased 
the relative risk further to 1.04 (0.79 to 1.37) and for a propensity score stratified analysis 
to 1.07 (0.85 to 1.37). There was no significant association between statin use and 
congenital malformations.20 
Ofori et al 
This observational retrospective cohort study10 consisted of 288 pregnant women 
screened through three population based registries called the Régie de l’Assurance 
Maladie du Québec (RAMQ) Med-Echo, and the fichier des événements démographiques 
du Québec using the following eligibility requirements: must be between 15 and 45 years 
old at first day of gestation, be insured with RAMQ’s drug plan for at least 12 months 
following gestation, and have filled a prescription for either a statin, fibrate, or nicotinic 
acid in the year before or during pregnancy. Eligible participants were grouped into 
women prescribed statins in their first trimester (group A = 153), women prescribed a 
fibrate/nicotinic acid in the first trimester (group B = 29), and women prescribed statins 
between 1 year and 1 month before conception but not during pregnancy (group C = 
106). The study measured the rate of congenital anomalies in infants diagnosed within the 
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first 12 months of life. Socio-demographic variables including maternal age, marital 
status (alone vs. cohabiting), number of years of education achieved, insurance status 
(welfare beneficiary vs. adherent), place of residence (urban vs. rural), were all included. 
Markers for health status included number of hospitalizations and emergency department 
visits, medical visits, prenatal visits, and women who had previous pregnancies were 
identified. Relevant chronic comorbidities that cause secondary hyperlipidemia included 
hypothyroidism, diabetes in the year before the pregnancy, gestational diabetes, 
hypertension in the year before the pregnancy. Ofori et al10 searched for these 
comorbidities using ICD-9 codes in the RAMQ/Med-Echo databases and the American 
Hospital Formulary Service to detect if they had filled prescription medications. Those 
who were on greater than two prescription medications other than statins or 
fibrates/nicotinic acid during pregnancy were examined to see whether the prescriptions 
were filled before and/or any length of time during pregnancy. Birth weights and 
premature births were accounted for due to an increased risk of premature infants to have 
congenital anomalies. Of those in group A (n = 153), using statins before and during their 
first trimester, 69 women (45%) had live births, 32 women (21%) had induced abortions, 
and 52 women (34%) had miscarriage/stillborn/unspecified abortion. Of those in Group B 
(n = 29), using fibrates/nicotinic acid before and during their first trimester, 15 women 
(52%) had live births, 4 women (14%) had induced abortions, and 10 women (34%) had 
miscarriage/stillborn/unspecified abortion. Of those in group C (n = 106), using statins 
only between 1 year and 1 month before pregnancy, 67 women (63%) had live births, 10 
women (10%) had induced abortions, and 29 women (27%) had 
miscarriage/stillborn/unspecified abortion. These pregnancy outcomes are summarized in 
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Figure I. Searching for the baby’s name, mother’s name, family name, and date of birth 
of the mother and baby, Ofori et al10 was able to link 64 of the 67 of the live births from 
group A, 14 of the 15 in group B, and 67 of the 67 in group C in to their medication and 
pregnancy database. The rate of congenital anomalies for group A was 3/64 (4.69%; 95% 
CI 1.00, 13.69). The rate for group B was 3/14 (21.43%; 95% CI 4.41, 62.57) and group 
C 7/67 (10.45%; 95% CI 4.19, 21.53). By comparison, the live-birth congenital anomaly 
rate in the rest of their registry was 6.97% (95% CI 6.77, 7.17). Adjusted OR for 
congenital anomalies for group A was 0.79 (95% CI 0.10, 6.02) and for group C 1.74 
(95% CI 0.27, 11.27), when compared with group B. The adjusted OR for group A was 
0.36 (95% CI 0.06, 2.18), when compared with group C. Ofori et al10 found no significant 
differences in the overall incidence of congenital anomalies in those that filled statin 
prescriptions during their first trimester of pregnancy compared to those who filled 
fibrates/nicotinic acid during their first semester of pregnancy or those who had filled a 
statin prescription within a year to a month of conception but discontinued statin therapy 
during their pregnancy.10 
Winterfield et al 
This prospective, controlled, observational study21 looked at pregnant women 
who contacted, or whose physicians contacted a Teratology Information Service (TIS) 
regarding statin exposure during their first trimester of pregnancy. There were 249 
women who met the criteria and were included in the study. Standardized methods22 were 
used by each center to collect data on maternal characteristics such as age, tobacco use, 
alcohol consumption, medical and obstetric histories were recorded and a corresponding 
control group of 249 additional women with similar demographics was formed. The time 
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during the pregnancy a statin was started, the duration the statin was taken and the dosage 
were recorded. After the expected delivery date, follow up was conducted via telephone 
interview or mailed questionnaire to either the woman or her physician. The follow-up 
data included pregnancy outcome, gestational age at delivery, birth weight, birth defects, 
and neonatal period. Statin therapy was started before conception in 89% of the exposed 
group. Close to half (48%) continued statin therapy beyond five weeks gestation and 21% 
beyond the seventh week. Of the exposed group, 6% continued therapy beyond the first 
trimester. The amount of live birth infants in the statin group was 194, and the control 
group was 224. Though there were 5 total major birth defects in the statin group, 8 were 
recorded when three were found to have congenital malformations in utero before being 
lost or electively terminated. The control group had 6 of 224 infants with congenital 
malformations. The rate of birth defects was not statistically significant (4.1% versus 
2.7% odds ratio 1.5; 95% confidence interval 0.5-4.5, P = 0.43).21 
DISCUSSION 
The increasing rate of obesity in the United States leading to more cardiac risk 
factors paired with half of pregnancies being unplanned has led to an increased number of 
pregnant women being exposed to a statin, a medication that is contraindicated in 
pregnancy (FDA Class X). Some argue to avoid statins completely in young women who 
are not using effective contraception because the possible inadvertent use during 
pregnancy.12,23 The focus of this systematic review was to evaluate the risk of birth 
defects in statin therapy during first trimester pregnancy.  
The results of all three studies10,20-21 did not detect any significant teratogenic 
effects of statins after exposure during the first trimester of pregnancy (Table II). These 
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negative findings support several published reports that there is no indication of increased 
risk for major birth defects with statin therapy during pregnancy.8-12 Ofori et al10 reported 
three congenital malformations with women who filled lovastatin, simvastatin and 
atorvastatin prescriptions. Their results support the prevailing theory that lipophilic 
statins tend to have high teratogenicity.24 Bateman et al20 found that 66 of the 73 statin-
exposed birth defects came from lipophilic statins. The results from Winterfield et al21 
had a contrary finding, showing that hydrophilic statins pravastatin and rosuvastatin had a 
higher association with birth defects. Winterfield et al,21 however, had no one in their 
study exposed to lovastatin, the lipophilic statin most infamous in literature for its 
hypothesized teratogenicity. 
Strengths 
Bateman et al20 used Medicaid Analytic eXtract, one of the largest and 
comprehensive medical databases. They found 1152 out of 886 996 completed 
pregnancies that had filled statin prescriptions during their first semester, which gave the 
study more precision in terms of risk assessment. The comprehensive database allowed 
the study to sort through and exclude comorbid conditions based on their severity as well 
as other factors. Taking into account these covariates enables adjustments to the study to 
yield more accurate findings. The original claims in the study were collected in a 
prospective manner so the data used is not susceptible to recall bias.  
Because Ofori et al10 used nicotinic or fibrates as their control group, they were 
able to match a control population that would resemble the statin group. Other studies 
tend to compare a statin group to a non-statin group. This meant that the non-statin group 
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would tend to have less comorbidities such as diabetes, hypertension, hypothyroid, renal 
impairment and would also tend to be younger. 
Winterfield et al21 as a prospective study was able to actively follow up to see if 
participants were compliant with their statin and recorded what day they had stopped 
using the drug. They also included non-live birth data on fetal malformations in both 
groups if they were found and before the fetus was miscarried or terminated. 
Limitations 
Bateman et al20 relied on coding to define the presence of a malformation. This 
indirect way of defining the outcome weakens the precision. They found, however, that 
when two or more codes are recorded on two different visits, the positive predictive value 
for correct diagnosis increases significantly.25 The same went for statin compliance. The 
nature of the study made it unable to verify whether patients took their statin. Since it is 
not safe to assume that a prescription that was filled was taken, considering only those 
who filled two prescriptions in their first trimester compromises sensitivity to strengthen 
specificity. Because only live births were included in this study, it does not take into 
account the fetal malformation rates prior to fetal termination. 
Ofori et al10 had a very small sample size (n = 135). Like Bateman et al20 and 
most studies in this area of interest, Ofori et al10 also only looked at live births. Live 
births represent only a portion of the true population that has the potential to show 
congenital malformations. As a retrospective study, Ofori et al10 was unable to confirm 
whether or not participants complied with their statin therapy and the exact day they 
discontinued. However, they cite that absolute noncompliance with medications obtained 
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by pregnant women is known to be low at about 8%.26 There is no citation, however, for 
relative noncompliance. 
Winterfield et al21 looked at the statin group as a homogenous group rather than 
inspecting each participant individually with the particular statin they were taking. 
Winterfield et al21 had a low sample size (n = 421). Research that looks at harm, 
particularly if the outcomes are rare, must have a large sample size to have more 
statistical authority. Another limitation is that since Winterfield et al21 relied on self-
reported data via telephone interviews or mail-in questionnaires, many potential 
confounders were likely underreported and hence not documented. An example of this is 
metabolic syndrome is associated with hyperlipidemia, but obesity was likely 
underreported.  
Due to the limitations and study design, these studies are not sufficient to change 
the current recommendations of statin use during pregnancy. Women in statin groups 
tend to have a higher incidence of diabetes mellitus, obesity, and advanced maternal age, 
all of which are associated with miscarriage, perinatal mortality, and congenital 
anomalies.27-31 Bateman et al20 had over 50% of its statin cohort between the ages of 30-
39, while only 13% of their control was at the same age. Furthermore, 45.1% of the statin 
group had pre-existing diabetes compared to 3.1% in the control.  
Research in this field remains promising. Hyperlipidemia, hypertension, 
cardiovascular disease, chronic kidney disease, and diabetes are often interrelated in 
individuals. Proving that statins may in fact benefit patients by keeping their lipid levels 
within normal limits and preventing the hypertension leading to preeclampsia can 
potentially be life-saving. Because the only ethical way to study statin exposure is by 
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observing accidental exposure, a large sample size is important for precision. At most, the 
current evidence can be used to reassure pregnant women with accidental exposure that 
birth defects are unlikely, which can prevent unnecessary elective terminations of 
pregnancy. Clinicians are urged to educate their statin patients on using effective 
contraception and to avoid taking their statin if pregnancy is possible.  
CONCLUSION 
Since they have been on the market, statins have always been considered 
contraindicated in pregnancy. Some researchers believe that statins have a role in 
preventing preeclampsia. Although most research in statin exposure during first trimester 
pregnancy seems to show no association, due to the statistical fragility of each study, 
there is not enough evidence to challenge the current recommendations to discontinue 
statin therapy during pregnancy. More research with larger sample sizes that look at the 
long-term effects is required to adequately assess the safety of statins during pregnancy. 
Though many questions still remain when looking at the risk of statins in pregnancy, the 
possibility of being able to control hyperlipidemia during pregnancy and prevent 
preeclampsia would greatly benefit the medical community. 
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Table I. Characteristics of Reviewed Studies   
Authors Study Design Limitations Inconsistency Indirectness Imprecision 
Publication 
bias 
Quality 
Bateman et 
al20 
Observational 
retrospective 
Downgrade Criteria 
Very 
Low Very 
Seriousab  
Not serious  Not serious  Not serious  None likely 
Ofori et al10 
Observational 
retrospective 
Seriousb  Not serious Not serious  Seriousc  None likely 
Very 
Low 
Winterfield 
et al21 
Observational 
prospective 
Seriousd Not serious  Not serious  Seriousc None likely 
Very 
Low 
aAuthors did not describe the dosing for statins 
bStudy only included live births 
cSmall sample size  
dConfounders such as maternal disease, comorbidities were not fully documented 
 
 
Table II. Summary of Findings 
Authors Study Design Group 
Number 
of Patients 
Number of 
congenital 
malformations 
(%) 
Relative Risk (95% CI) 
Unadjusted 
Stratified on 
Diabetes 
Propensity Score 
Stratified 
Bateman 
et al20 
Retrospective 
Statin 1152 73 (6.34) 1.79 (1.43 - 2.23) 1.34 (1.07 - 1.68) 1.07 (0.85 - 1.37) 
No statin 885 844  31 416 (3.55) Referent Referent Referent 
        
Authors Study Design Group 
Number 
of Patients 
Number of 
congenital 
malformations 
95% CI 
Adjusted OR for Congenital Anomalies 
group A: group C (95% CI) 
Ofori et 
al10 
Retrospective 
Prescribed 
statins only 
before and 
during first 
trimester (Group 
A) 
64 3 (4.69) 1.00 - 13.69 
0.36 (0.06, 2.18) 
Fibrate/nicotinic 
acid (Group B) 
14 3 (21.43) 4.41 - 62.57 
Prescribed 
statins only 
between 1 year 
and 1 month 
before pregnancy 
(Group C) 
67 7 (10.45) 4.19 - 21.53 
        
Authors Study Design Group 
Number 
of Patients 
Number of 
congenital 
malformations 
to live births 
(%) 
OR (95% CI) P-Value 
Winterfiel
d et al21 
Prospective 
Statin 249 8/197 (4.1) 
1.5 (0.5 to 4.5) 0.43 
No statin 249 6/224 (2.7) 
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FIGURE I 
 
 
